SEC Form 4 · accession 0001104659-17-006441
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon Read
Officer — Chief Scientific Officer
Period of report
Feb 1, 2017
Accepted (ET)
Feb 3, 2017 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $16.64 | Feb 1, 2017 | A | 67,500 | A | — | Feb 1, 2027 | Common Stock | 67,500 | 67,500 | D |
Explanation of responses
- F1These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date, provided that the first vesting shall not occur until April 1, 2017, and on such first vesting date, the total number of monthly installments between the grant date and April 1, 2017 shall vest.